Royalty Pharma enters the final stretch of August with an awkward split: options positioning remains at its most call-heavy reading of the past year while the executives running the company have been selling into the strength.
The options signal established last week has not faded. The put/call ratio dropped further to 0.14 on Friday — 3.3 standard deviations below its 20-day mean of 0.20 — and remains near the bottom of its 52-week range of 0.09 to 1.44. That is a historically lopsided lean toward calls, sustained now across multiple sessions rather than a one-day expiry artefact. The borrow market adds no friction for bears: availability is essentially unlimited, with over 200 million shares available to lend against roughly 10.5 million shorted — a ratio so wide that short sellers face no meaningful cost or scarcity. Cost to borrow has ticked up sharply on a percentage basis, rising 34% over the week to 0.67%, but the absolute level remains trivially low. Short interest itself has continued to drift lower, now at 2.5% of the free float versus roughly 2.9% a month ago. The positioning picture, taken together, is firmly bullish-leaning on the options side and uncrowded on the short side — with no lending-market tension to complicate either read.
The insider activity cuts the other way. Executive Vice Chairman Christopher Hite sold $6 million worth of stock on August 18 at $59.97, a material transaction that follows earlier sales of $1.7 million in late June. CFO Terrance Coyne also sold just over $645,000 across two transactions on August 13. Both trades landed after a run of stock awards distributed on August 5 — suggesting some of the selling is plan-driven — but the cluster is notable given the stock's 5% gain over the past month to $61.31. Founder and CEO Pablo Legorreta received an award of 65,216 shares on August 5 and appears to be holding. On the institutional side, Capital Research added 1.8 million shares in the most recent period while BlackRock added 1.9 million — two of the larger active positions building at current levels.
The Street remains constructive and has been raising its view through the summer. JP Morgan's Chris Schott lifted his price target to $62 from $58 on August 7 after the Q2 print, maintaining an Overweight rating. That follows TD Cowen raising to $65 from $50 in mid-July, and Citigroup and Morgan Stanley both lifting targets in prior months. The cluster of upgrades and target increases through Q2 reflects building conviction in the royalty stream's durability. Consensus is a hold by count, but the analyst target cluster from active coverage sits in the $62–$66 range against a current price of $61.31 — modest upside on the mean, but meaningful upside against the more bullish calls. On valuation, the PE has eased to 10.5x over the past month while EV/EBITDA has compressed slightly to 10.9x — neither extreme, and consistent with a royalty model that trades on cash flow predictability rather than growth optionality. The forward EPS growth factor ranks in the 94th percentile of the universe, a standout score that underpins the bull case: the royalty portfolio keeps generating durable cash flows without the pipeline risk that is currently pressuring peers like MRK and LLY, both of which rallied hard this week but remain under pressure from broader sector rotation.
The next scheduled earnings event is November 6. The two most recent results produced muted same-day moves — down 0.4% in August and up 1.2% in the prior quarter — with slightly stronger five-day drifts of around 2–3% in both cases. That pattern suggests the market treats RPRX as a slow-burn rather than an event-driven name, which makes the sustained options skew the more interesting signal to track heading into the autumn.
The question worth watching next week is whether the extreme call skew — now in its second consecutive week at multi-standard-deviation lows on the PCR — starts to normalise as the immediate post-earnings positioning unwinds, or whether fresh buying continues to hold it at these levels despite the insider selling pressure.
See the live data behind this article on ORTEX.
Open RPRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
